Imperial College London

Dev Vyas, in collaboration with the Jupiter Research Institute, shapes a new era of financial technology and education for the future.

Retrieved on: 
Thursday, April 4, 2024
Intelligence, Perseverance, Blockchain, Education, Knowledge, Max Group, University, Jupiter Fund Management, Imperial College London, Fintech, Mecklermedia, Management

This story of innovation, pursuit, and collaboration centers on Dev Vyas, a financial pioneer born in Mumbai, who closely partners with the Jupiter Research Institute to draw a hopeful blueprint for the future.

Key Points: 
  • This story of innovation, pursuit, and collaboration centers on Dev Vyas, a financial pioneer born in Mumbai, who closely partners with the Jupiter Research Institute to draw a hopeful blueprint for the future.
  • When the Jupiter Research Institute sought a leader to guide the institution to the forefront of fintech innovation, Dev naturally became their top choice.
  • The Jupiter Research Institute chose Dev not only for his personal accomplishments but also for his vision and values that benefit the broader society.
  • Upon joining the Jupiter Research Institute, Dev injected his precise insights into the financial markets and passion for education into the institution's daily operations.

Hazelcast Announces Stephen Weston as Chief Scientist

Retrieved on: 
Thursday, April 4, 2024
Volvo, Organization, Target, Risk management, Learning, Ernst & Young, Science, Internet of things, Financial services, Research, Global 2000, Imperial College London, Fintech, JPMorgan Chase, Machine learning, Medical device

Palo Alto, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Hazelcast, Inc. , the company that enables instant action on all data, announces Dr. Stephen Weston as its chief scientist, bringing deep ML and AI expertise to Hazelcast’s leadership in AI application and data infrastructure.

Key Points: 
  • Palo Alto, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Hazelcast, Inc. , the company that enables instant action on all data, announces Dr. Stephen Weston as its chief scientist, bringing deep ML and AI expertise to Hazelcast’s leadership in AI application and data infrastructure.
  • Weston, a Ph.D. in mathematical finance, brings 30 years of experience to the role in areas such as AI, risk management, and mathematical modeling.
  • In addition to his position as chief scientist at Hazelcast, Weston supervises academic research in the department of computing at Imperial College London, where the research group develops models that integrate technology, science and finance.
  • He and Weston are leading a deep bench of fintech and AI experts at Hazelcast.

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

Rigetti Computing Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
PIN, Sale, Standard Chartered, Fermilab, Quantum, Oak Ridge National Laboratory, Partnership, Electronics, AFRL, Software, Computer, AWS, Air Force Research Laboratory, Innovation, Rigetti Computing, Research, University, SQMS, Imperial College London, Architecture, QPU, Amazon Web Services, Machine learning, Innovate UK, Engineering, SBRI, HPC, IDIQ, Aalto University, Collection, DARPA, Government

BERKELEY, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • BERKELEY, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the fourth quarter and year ended December 31, 2023.
  • As part of the project, Rigetti proposes to develop and deploy a 24-qubit quantum computer based on the Company’s Ankaa-class architecture.
  • In December 2023, Rigetti launched the Novera QPU (quantum processing unit), a 9-qubit QPU based on the Company’s Ankaa™-class chip architecture.
  • ET, or 2:00 p.m. PT, to discuss its fourth quarter 2023 and full year 2023 financial results.

Beckley Retreats Celebrates a Year of Growth and Accelerating Demand for Legal Psychedelic Retreats

Retrieved on: 
Wednesday, March 13, 2024
The Walt Disney Company, Veteran, Walt Disney World, Life, Imperial College London, Traumatic brain injury, Economist, Tourism

The company also announced a round of extremely positive feedback in the form of an 83 Net Promoter Score in 2023 and new and expanding initiatives for the coming year.

Key Points: 
  • The company also announced a round of extremely positive feedback in the form of an 83 Net Promoter Score in 2023 and new and expanding initiatives for the coming year.
  • In addition to its paying guests, Beckley Retreats funded $150,000 in scholarships in 2023 to participants from low-income or underserved communities.
  • It also hosted free retreats for 21 veterans of military conflicts as part of an ongoing program with Heroic Hearts and Imperial College London to explore the effects of psychedelic therapy on Traumatic Brain Injury.
  • “We truly are changing lives and setting the standard for psychedelic retreat programs,” said Neil Markey, co-founder and CEO of Beckley Retreats.

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Health Technology, Genetics, Other Science, Research, Science, Genomics, IHC, Methylation, Partnership, Laser, TMB, NGS, MSI, DNA, Biomarker, Cancer, Hydrofluoroolefin, Biology, Medicine, Imperial College London, AACR, Microsatellite instability, Neoplasm, Therapy, Agilent Technologies, Liquid biopsy, Machine learning, RNA-Seq, University of Oxford, CMO, Medical imaging

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .
  • Agilent Avida - Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample.
  • Agilent SureSelect Cancer Custom panels - Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays.
  • AACR attendees can also explore multiple Agilent research posters and over 50 additional customer posters highlighting Agilent instruments and solutions.

Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant

Retrieved on: 
Tuesday, March 19, 2024
Health, Fitness & Nutrition, Clinical Trials, Research, Pharmaceutical, Science, International Menopause Society, VMS, Menopause, OASIS, Executive Committee, Imperial College London, Woman, Hot, Safety, Elinzanetant, Phase, Marketing, Pharmaceutical industry

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.

Key Points: 
  • Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.
  • The long-term safety profile observed over 52 weeks in the OASIS 3 study is overall consistent with previously conducted studies and published data1,2 on elinzanetant.
  • “OASIS 3 was designed to address the important question of the long-term profile of elinzanetant.
  • “These results, coupled with the recent announcement of topline data for OASIS 1 and OASIS 2, strengthen our confidence in the proposed efficacy and safety of elinzanetant as a potential novel non-hormonal solution for women experiencing menopause-related symptoms.”
    OASIS 3 (NCT05030584) is the third Phase III study in the OASIS clinical development program with positive topline results.

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

Retrieved on: 
Thursday, March 14, 2024
Software, Telemedicine, Virtual Medicine, Finance, Health, Health Technology, Professional Services, Technology, Apps, Applications, Research, The Wall Street Journal, Growth, Clinical professor, Mayo Clinic, Telehealth, SHL, Imperial College London, Clinical trial, Wells Fargo, FINRA, Pharmaceutical industry

SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target.

Key Points: 
  • SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target.
  • This price target represents a significant premium over the company's current share price, highlighting the firm's confidence in SHL's growth trajectory and market position.
  • The equity research report emphasizes SHL Telemedicine's innovative approach and expanding market opportunities, noting that "SHLT is a pure-play in the rapidly expanding $115B telemedicine market.
  • The $11.00 price target is based on a comprehensive analysis of the company's financial health, growth prospects, and the expanding market for telemedicine services.

Enhanced Games respond to White House "Deep Concern"; Invite Collaboration with IOC

Retrieved on: 
Monday, March 18, 2024
Olympic Games, Conference, Prevalence, Sport, Frailty, Science, Professor, Partnership, White, Journal, Research, Tobacco, MD, Athlete, Parliament, Imperial College London, IOC, Cannabis, Enhanced, Sports medicine, Lancet, WADA, Entertainment

The Enhanced Games respond to "deep concern" comments from the White House with a pledge to unwavering commitment to fairness in sports competition, supported by rigorous science.

Key Points: 
  • The Enhanced Games respond to "deep concern" comments from the White House with a pledge to unwavering commitment to fairness in sports competition, supported by rigorous science.
  • In a bid to foster informed discourse, the Enhanced Games extend an invitation to the IOC and the White House to engage in collaborative dialogue, just as the British Parliament did by convening the First Conference on Human Enhancement in collaboration with the Enhanced Games last month.
  • Only with a formal partnership between the IOC and Enhanced Games, can Olympics drug testing finally be effective and ensure the integrity of their games."
  • Journalists are invited to join one of two virtual press conferences with Dr Aron D'Souza, President of the Enhanced Games:

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.